Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and ...
The FDA approved neoadjuvant Imfinzi, gemcitabine and cisplatin, followed by adjuvant Imfinzi after radical cystectomy in ...
This approval of durvalumab marks the first and only perioperative immunotherapy regimen available in muscle-invasive bladder ...
Trisha Wise-Draper, MD, PhD, discusses anticipated data on head and neck cancers and their potential impact on the field.
The addition of concurrent cisplatin to adjuvant radiation therapy conferred no benefit to women with intermediate-risk, ...
Adding adjuvant chemotherapy to radiotherapy did not lead to a significant survival benefit over radiotherapy alone in women ...
The National Health Fund (NHF) has announced that effective March 27, 2025, attention deficit hyperactivity disorder (ADHD) and cervical cancer are covered on the NHF's Card Programme, bringing the ...
Results from the NRG Oncology GOG-0263 Phase III clinical trial testing the addition of cisplatin-based chemotherapy to ...
The FDA has approved neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab after radical cystectomy in MIBC.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback